Kymera Therapeutics, Inc. (KYMR) Financial Statements
Kymera Therapeutics, Inc. (KYMR) reported trailing twelve-month revenue of $105.0M (up 134.8% year on year) and net income of -$299.6M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$238.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
KYMRKymera Therapeutics, Inc.Follow KYMR — free
—
Price chart with a free account
- Market cap
- 9.2B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.03 | 0.07 | 0.05 | 0.08 | 0.05 | 0.04 | 0.10 | |
| Gross profit | — | — | — | — | 0.00 | 0.00 | — | |
| Research & development | 0.06 | 0.14 | 0.16 | 0.19 | 0.24 | 0.32 | 0.38 | |
| Operating income | -0.05 | -0.10 | -0.16 | -0.17 | -0.26 | -0.35 | -0.35 | |
| Pre-tax income | -0.05 | -0.10 | -0.15 | -0.15 | -0.22 | -0.31 | -0.30 | |
| Income tax | 0.00 | 0.00 | 0.00 | — | — | 0.00 | — | |
| Net income | -0.05 | -0.10 | -0.15 | -0.15 | -0.22 | -0.31 | -0.30 | |
| Diluted EPS ($) | -3.15 | -2.09 | -2.87 | -2.52 | -2.98 | -3.69 | -3.06 | |
| Diluted shares (bn) | — | — | 0.054 | 0.058 | 0.075 | 0.084 | — |
USD billions · SEC XBRL
Kymera Therapeutics, Inc. — questions
- What is Kymera Therapeutics, Inc.'s revenue?
- $105.0M over the twelve months to 2026-06-30, up 134.8% year on year, from its 10-Q and 10-K filings.
- What is Kymera Therapeutics, Inc.'s net income?
- -$299.6M over the twelve months to 2026-06-30.
- What is Kymera Therapeutics, Inc.'s free cash flow?
- -$238.0M over the twelve months to 2026-06-30.
- What are Kymera Therapeutics, Inc.'s diluted earnings per share?
- $-3.06 over the twelve months to 2026-06-30.
Every figure on this page comes from Kymera Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.